Evidera, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Evidera, Inc. - overview
Established
2013
Location
Bethesda, MD, US
Primary Industry
Biotechnology
About
Evidera, Inc. specializes in providing real-world data and evidence solutions, focusing on health economics and patient-centered research services for the pharmaceutical and biotechnology sectors. Founded in 2013 and headquartered in Bethesda, US, Evidera, Inc. delivers comprehensive research services aimed at enhancing healthcare decision-making.
The company was acquired by Pharmaceutical Product Development in September 2016 from Symphony Technology Group. Evidera has successfully completed 2 deals with its most recent deal occurring on August 9, 2016. Evidera and CorEvitas Solutions, integrated into PPD™ clinical research under Thermo Fisher Scientific, offer a diverse array of services that include PPD™ CorEvitas™ Clinical Registries, PPD™ CorEvitas™ Precision Medicine, PPD™ Evidera™ Health Economics & Market Access, PPD™ Evidera™ Patient-Centered Research, and PPD™ Evidera™ Real-World Data & Scientific Solutions. Their focus is to improve decision-making and patient outcomes through data-driven insights provided to clients in the biopharmaceutical industry across North America, Europe, and Asia-Pacific.
Evidera and CorEvitas Solutions generate revenue from a structured model encompassing subscriptions, partnerships, and direct service agreements within the healthcare and pharmaceutical sectors. Their financial framework primarily relies on B2B partnerships for access to their research services and data solutions, with flagship products like PPD™ Evidera™ Real-World Data & Scientific Solutions playing a central role in their revenue model. The acquisition by Pharmaceutical Product Development on August 9, 2016, is expected to bolster Evidera's growth strategy. The company aims to develop new products and enhance its services, focusing on expanding into new geographic markets.
Specific regions targeted for expansion include Asia-Pacific by 2025, aiming to address unique healthcare challenges in this area. The recent acquisition will support these initiatives through increased resources and capabilities.
Current Investors
Carlyle Group, Hellman & Friedman, PPD, Inc.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.evidera.com
Verticals
HealthTech
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Evidera, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Medimix International | - | ||||||||
| Add-on, Trade Sale | Completed | Evidera, Inc. | - | ||||||||
| Add-on, Trade Sale | Completed | Archimedes Pharma Limited | - | ||||||||
| Buyout | Completed | Evidera, Inc. | - |
Displaying 1 - 4 of 4
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.